Нажмите сюда, чтобы получить доступ к карте офисов и заводов компании Октафарма. Если вам необходима информация о подразделении компании, не представленном в данном списке, пожалуйста, обратитетсь в Центральный офис компании.
Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A
Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia. The study...
Octapharma donates 30.5 million international units of its medicine Nuwiq® to treat people with haemophilia in developing countries
Lachen, Switzerland, November 21st, 2017: Octapharma is pleased to
announce the completion of a charitable donation of 30.5 million
international units of its human cell-line derived recombinant factor
VIII product, Nuwiq®, in...
Octapharma USA Grant Supports Mission of First Hemophiliac to Climb the Seven Summits of the World
Hoboken, New Jersey, October 31st 2017: Octapharma USA has provided a
grant to support the final leg of the inspirational journey of Chris
Bombardier, who hopes to become the first person with severe Hemophilia
Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements
Hoboken, New Jersey, August 29th 2017: Octapharma USA sponsored the
National Hemophilia Foundation’s 69th Annual Meeting in Chicago and
provided a patient symposium sharing the inspirational stories of three
young men with...
Publication of clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq® in previously untreated patients
Lachen, Switzerland, August 23rd 2017: Octapharma is delighted to
announce the publication of interim data from the NuProtect study
(GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq®
Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with Von Willebrand disease (VWD) and haemophilia A
Lachen, Switzerland, July 11th 2017: Octapharma is pleased to announce
the success of yesterday’s symposium at the International Society on
Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As
ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A
Lachen, Switzerland, July 10th 2017: Octapharma is playing a prominent
role this week at the International Society on Thrombosis and
Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of
Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany
Lachen, Switzerland, July 6th, 2017 – Octapharma today announced that it
will be actively involved in a wide range of activities at this year’s
International Society on Thrombosis and Haemostasis (ISTH) Congress. The
Octapharma donates Nuwiq® to the WFH Humanitarian Aid Program to provide patients with haemophilia A in developing countries access to therapy
Lachen, Switzerland, December 22nd, 2016: Octapharma is proud to
announce that the company has made a charitable donation of 4.5 million
units of its fourth generation, human cell-line derived recombinant
factor VIII product,...
Press release - The French Health and Sports Minister grants the founder of the Octapharma Group, Mr. Wolfgang Marguerre, the French Legion of Honor during a visit to Octapharma' s facilities in Lingolsheim, France.